Obeldesivir (GS-5245) is an oral prodrug of GS-441524, a nucleoside analog that inhibits the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2. It undergoes intracellular conversion to the active nucleoside triphosphate GS-443902, which incorporates into viral RNA and causes chain termination. In vitro, Obeldesivir demonstrates potent antiviral activity against SARS-CoV-2 with EC₅₀ values ranging from 0.47 to 1.09 μM in human airway epithelial and lung cell lines. In vivo studies in SARS-CoV-2-infected mice and hamsters show that oral administration significantly reduces viral titers in the lung and improves clinical outcomes. Compared to remdesivir, Obeldesivir offers better oral bioavailability and tissue penetration, making it a promising candidate for outpatient COVID-19 treatment.
MedKoo Cat#: 124427
Name: Obeldesivir
CAS#: 2647441-36-7
Chemical Formula: C16H19N5O5
Exact Mass: 361.1400
Molecular Weight: 361.36
Elemental Analysis: C, 53.18; H, 5.30; N, 19.38; O, 22.14
The following data is based on the product molecular weight 361.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
